All lobbying filings

Indivior Inc.

Indivior Inc. filed a Q1 report for Indivior Inc. on April 21, 2025.

Lobbying for Indivior Inc.

As filed: INDIVIOR INC for INDIVIOR INC.

All filings by Indivior Inc. · Everything Indivior Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$230,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Virginia

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

SUPPORT for Patients and Communities Reauthorization Act (HR 2483); HALT Fentanyl Act (HR 27 / S 331); Reentry Act (HR 2586); Due Process Continuity of Care Act (HR 1510); FY25 and 26 appropriations for Labor-HHS-Education, Military Construction & Veterans Affairs, and Commerce-Justice Science; FY25 Continuing appropriations (HR 1968); FY26 budget resolution (H Con Res 14); DEA rulemaking on telemedicine prescribing of controlled substances (RIN #1117-AB40)

Bills named in this filing 6

H.R. 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
H.R. 27
HALT Fentanyl Act
H.R. 2586
Reentry Act of 2025
H.R. 1510
Due Process Continuity of Care Act
H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
H. Con. Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.